Use of Fixed-Dose Combination Drugs for the Treatment of Glaucoma
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 24 (12) , 1007-1016
Abstract
Glaucoma is a leading cause of irreversible visual loss. This potentially blinding disease is a progressive optic neuropathy associated with elevated intraocular pressure (IOP). Initial therapy for glaucoma typically consists of topical medications or laser treatment to lower IOP. Frequently, more than one medication is required to achieve adequate control of IOP. However, more medications means more bottles and greater complexity for the patient. There are several potential benefits of fixed combination medications compared with using the individual components separately. These include a reduction in the total number of drops and preservative instilled per day, cost savings, improved tolerability and compliance and avoiding the washout effect resulting from rapid-sequence instillation of multiple drops. Attempts to develop effective fixed combinations of glaucoma medications date back several decades. In recent years, fixed combinations of commonly paired drugs have been approved by various regulatory bodies in different countries and have gained wide acceptance. Current commercially available, fixed combination drugs include the topical β-adrenoceptor antagonist timolol 0.5% combined with a prostaglandin, a topical carbonic anhydrase inhibitor or an α-adrenoceptor agonist. Although there is no uniformity among registration trial designs, most published literature compares the efficacy of the fixed combination to the individual components and to concomitant use of both components. Various factors inherent to study design such as medication run-in, washout periods and peak and trough effects have to be taken into consideration when analysing the demonstrated efficacy of fixed combinations. Fixed combination treatments offer effective IOP control while reducing the washout effect and exposure to preservatives. They are also convenient. However, fixed combinations also remove the possibility of titrating the individual components both in terms of concentration and timing of administration. In addition, fixed combinations might not always provide the same efficacy as proper use of the individual components. The clinician must make individualised assessments when weighing the convenience of these medications against their limitations for specific patients.Keywords
This publication has 54 references indexed in Scilit:
- Patient Perspectives in Glaucoma Care: Introduction to the american journal of ophthalmology SupplementAmerican Journal of Ophthalmology, 2006
- Brimonidine and Timolol Fixed-Combination Therapy Versus Monotherapy: A 3-Month Randomized Trial in Patients with Glaucoma or Ocular HypertensionJournal of Ocular Pharmacology and Therapeutics, 2005
- Is Addition of a Third or Fourth Antiglaucoma Medication Effective?Journal of Glaucoma, 2004
- Comparison of the Efficacy of the Fixed-Combination Timolol/Dorzolamide Versus Concomitant Administration of Timolol and DorzolamideJournal of Ocular Pharmacology and Therapeutics, 2003
- Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists’ officesCurrent Medical Research and Opinion, 2003
- A comparison of dorzolamide–timolol combination versus the concomitant drugsAmerican Journal of Ophthalmology, 2000
- Intraocular Pressure-Lowering Effects of Latanoprost Monotherapy versus Latanoprost or Pilocarpine in Combination with TimololJournal of Glaucoma, 1999
- The efficacy and safety of the Dorzolamide—timolol combination versus the concomitant administration of its components11Ms. Strohmaier and Drs. Snyder and Adamsons are employees of Merck & Co., Inc, the manufacturer of the dorzolamide-timolol combination. Dr. DuBiner has no proprietary interest in the dorzolamide-timolol combination or Merck.Ophthalmology, 1998
- Costs of Treating Primary Open-Angle Glaucoma and Ocular HypertensionJournal of Glaucoma, 1998
- Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.British Journal of Ophthalmology, 1995